Hengrui Pharma(SH:600276) Ge Long Hui A P P·2025-07-31 09:04Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have received approval from the National Medical Products Administration for clinical trial notifications regarding SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection, with trials set to commence shortly [1]. Company Summary - Heng Rui Medicine's subsidiaries have been granted clinical trial approval for three new drug candidates [1]. - The approved drugs include SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection, indicating a focus on expanding their product pipeline [1]. - The initiation of clinical trials represents a significant step in the development of these drugs, potentially leading to future market opportunities [1].